Quantum Biopharma Ltd.(QNTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNTM Quantum Biopharma Ltd.

Pre-Mkt 01-22 05:10:10 EST

6.42

-0.80

-11.08%

High7.21	Low6.25	Vol67.81K
Open7.00	D1 Closing7.22	Amplitude13.30%
Mkt Cap24.67M	Tradable Cap22.80M	Total Shares3.84M
T/O449.39K	T/O Rate1.91%	Tradable Shares3.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QNTM","market":"US","secType":"STK","nameCN":"Quantum Biopharma Ltd.","latestPrice":6.42,"timestamp":1769029200000,"preClose":7.22,"halted":0,"volume":67807,"delay":0,"changeRate":-0.11080332409972297,"floatShares":3551691,"shares":3842977,"eps":-10.097511,"marketStatus":"Pre-Mkt","change":-0.8,"latestTime":"01-22 05:10:10 EST","open":7,"high":7.2099,"low":6.25,"amount":449387.7937201,"amplitude":0.13295,"askPrice":7,"askSize":100,"bidPrice":5.88,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-10.097511,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769092200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":6.42,"postHourTrading":{"tag":"盘后","latestPrice":6.42,"preClose":6.42,"latestTime":"19:20 EST","volume":390,"amount":2615.4513,"timestamp":1769041223080,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3338487233368317},"requestUrl":"/m/hq/s/QNTM/tweets","defaultTab":"tweets","newsList":[{"id":"2593541883","title":"Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2593541883","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593541883?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:00","pubTimestamp":1766494800,"startTime":"0","endTime":"0","summary":"Studies Will Support Investigational New Drug Application (IND) with the US FDA, Including Design of Phase 2 TrialTORONTO, Dec.  23, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CS","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/23/3209828/0/en/Quantum-Biopharma-Announces-Completion-of-Dosing-in-180-Day-Repeated-Dose-Oral-Toxicity-and-Toxicokinetic-Studies-for-Lucid-21-302-Lucid-MS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0971096721.USD","LU1989772923.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0106831901.USD","LU0314104364.USD","QNTM","LU0158827781.USD","LU1548497426.USD","LU0528227936.USD","LU0912757837.SGD","LU1244550577.SGD","LU1720051108.HKD","LU0557290698.USD","BK4585","BK4588","LU0158827948.USD","LU0320765646.SGD","LU1732800096.USD","BK4581","LU2089284900.SGD","LU0098860793.USD","BK4516","LU1244550494.USD","BK4127","LU2357305700.SGD","IND","LU2089283258.USD","LU2271345857.HKD","LU0267386448.USD","LU1363072403.SGD","LCID","LU0795875086.SGD","LU1244550221.USD","LU1732799900.SGD","LU1162221912.USD","LU1989772840.SGD","BK4534","LU0006306889.USD","LU1668664300.SGD","BK4596","LU0882574139.USD","LU1791710400.SGD","LU2111349929.HKD","BK4555","BK4551","LU2133065610.SGD","BK4099","LU0234570918.USD","LU0795875169.SGD"],"gpt_icon":0},{"id":"2592382113","title":"World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592382113","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592382113?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:52","pubTimestamp":1766181120,"startTime":"0","endTime":"0","summary":"TORONTO, Dec.  19, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), understands that Quantum BioPharma shareholder Paul Durkacz has filed ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/19/3208756/0/en/World-Renowned-Law-Firm-Grant-Eisenhofer-Files-Class-Action-Lawsuit-Against-Canadian-Banks-CIBC-and-RBC-Alleging-Illegal-Stock-Market-Manipulation-of-Quantum-BioPharma-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNTM","BK4007"],"gpt_icon":0},{"id":"2588223607","title":"Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2588223607","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588223607?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590400,"startTime":"0","endTime":"0","summary":"TORONTO, Dec.  01, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flag","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196861/0/en/Investigative-News-Program-W5-Airs-Final-Segment-on-USD-700-Million-Stock-Market-Manipulation-Lawsuit-of-Quantum-Biopharma-Involving-CIBC-and-RBC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2028103732.USD","LU0557290698.USD","LU2089284900.SGD","LU1791710400.SGD","BK4516","LU2089283258.USD","QNTM","BK4504","IE00BKVL7J92.USD","USD","LU0106831901.USD","LU0314104364.USD","LU0225283273.USD","LU1668664300.SGD","LU1074936037.SGD","LU1244550494.USD","LU0795875169.SGD","LU1162221912.USD","LU1363072403.SGD","LU0106261372.USD","LU2357305700.SGD","LU2023251221.USD","BK4127","IE00BZ1G4Q59.USD","LU2271345857.HKD","LU0882574139.USD","LU1244550577.SGD","LU1989772840.SGD","LU0006306889.USD","LU1791710582.SGD","LU0098860793.USD","LU1548497426.USD","LU0158827948.USD","LU0971096721.USD","LU0795875086.SGD","BK4007","BK4585","BK4534","LU1732799900.SGD","BK4581","LU1720051017.SGD","LU1732800096.USD","BK4588","LU0912757837.SGD","LU0320765646.SGD","LU2347655156.SGD","LU2111349929.HKD","LU1244550221.USD","LU0267386448.USD","LU2133065610.SGD"],"gpt_icon":0},{"id":"2586022084","title":"Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2586022084","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586022084?lang=en_us&edition=fundamental","pubTime":"2025-11-28 05:00","pubTimestamp":1764277200,"startTime":"0","endTime":"0","summary":"TORONTO, Nov.  27, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flag","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/27/3195939/0/en/Award-winning-Investigative-News-Program-W5-Airs-Part-2-of-3-part-Television-Series-on-Alleged-Stock-Market-Manipulation-of-Quantum-Biopharma-Involving-Two-of-Canada-s-Largest-Bank.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4551","BK4596","BK4007","QNTM","BK4099","LCID"],"gpt_icon":0},{"id":"2586840601","title":"Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5","url":"https://stock-news.laohu8.com/highlight/detail?id=2586840601","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586840601?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:00","pubTimestamp":1764104400,"startTime":"0","endTime":"0","summary":"TORONTO, Nov.  25, 2025   -- Quantum BioPharma Ltd.    , is pleased to announce that national television network CTV News’ flagship investigative program W5 will air, starting today, a three-part series about Quantum Biopharma and the company’s allegations of stock market manipulation. Top CTV News journalist and W5 investigative reporter Jon Woodward describes Part One of the series in an article entitled, “Was a Canadian company’s multiple sclerosis research nearly derailed by ‘market manipulation’?”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194699/0/en/Quantum-Biopharma-s-USD-700-Million-Lawsuit-Alleging-Stock-Market-Manipulation-Subject-of-3-part-Series-Investigative-News-Program-W5.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USD","BK4555","QNTM","BK4596","LCID","BK4099","BK4551","BK4007"],"gpt_icon":0},{"id":"2581004834","title":"Quantum Biopharma Ltd  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581004834","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581004834?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:11","pubTimestamp":1762553467,"startTime":"0","endTime":"0","summary":"Quantum Biopharma Ltd  expected to post a loss of22cents a share - Earnings Preview Quantum Biopharma Ltd QNTM.CD  is expected to  show a rise in quarterly revenue when it reports  results on November","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ306:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNTM","BK4007"],"gpt_icon":0},{"id":"2581288869","title":"Quantum BioPharma's digital asset portfolio has achieved a $572,000 return since the beginning of the year","url":"https://stock-news.laohu8.com/highlight/detail?id=2581288869","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581288869?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:44","pubTimestamp":1762519440,"startTime":"0","endTime":"0","summary":"BlockBeats News, November 7th, Canadian biopharmaceutical company Quantum BioPharma Ltd. (QNTM) announced in its third-quarter financial and operational performance that year-to-date, the company has realized a $572,000 profit from its primarily Bitcoin-based digital asset portfolio.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"theblockbeats_live","url":"https://www.theblockbeats.info//en/flash/319584","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/319584","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["83042","QNTM","BK4588","BK4601","BK4007","03042","09042","BK4594","BTC.USD.CC","03008","09439","BK4585","BK1611","BTC.USD.HKCC","03439"],"gpt_icon":0},{"id":"2581893007","title":"Press Release: Quantum Biopharma Reports Strong Third Quarter Results Maintaining 'No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2581893007","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581893007?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:00","pubTimestamp":1762516800,"startTime":"0","endTime":"0","summary":"The Company remains in a strong financial position. A quarter-over-quarter comparison of Q3 2025 with Q2 2025 highlights a period of significant strengthening, with a 275% increase in shareholder equity, an 86% reduction in the debt-to-equity ratio, a 50% decrease in total liabilities, primarily due to the elimination of all liabilities associated with the previously issued convertible debentures, and an 8% reduction in General and Administrative expenses. Year to date, the Company has realized gains of US$572,000 from its digital asset portfolio, which is comprised mainly of Bitcoin. The company reaffirms its \"no going concern\" status, and management believes that existing capital resources are sufficient to maintain operations beyond March 2027.Specifically, comparing Q3 2025 with Q2 2025, Quantum BioPharma has achieved:. -- A 50% reduction in total liabilities, decreasing from US$13.2M to. US$7.5M , as a direct result of the above decrease in liabilities;-- An 87% reduction in the C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4596","LU1732800096.USD","BK4504","LU0106261372.USD","IE00BZ1G4Q59.USD","BK4127","LU0006306889.USD","LU0158827781.USD","BK4099","QNTM","TM","IPO","LU2028103732.USD","BK4588","BK4516","LU1074936037.SGD","LU2089283258.USD","LU0267386448.USD","BK4555","LU1989772923.USD","LU0795875169.SGD","BK4581","LU2089284900.SGD","LU1720051017.SGD","LU0225283273.USD","LU0557290698.USD","BK4534","03160","BTC.USD.CC","LU0098860793.USD","IE00BKVL7J92.USD","LU1989772840.SGD","LU2111349929.HKD","LU1363072403.SGD","USD","LU2271345857.HKD","LU1162221912.USD","LU0971096721.USD","LU0795875086.SGD","LU1244550221.USD","BK4604","LU0158827948.USD","LU0234570918.USD","BTC.USD.HKCC","LU1732799900.SGD","BK4585","LU1244550577.SGD","LCID","LU2023251221.USD","LU1720051108.HKD"],"gpt_icon":0},{"id":"2580429410","title":"Quantum BioPharma Ltd. Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2580429410","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580429410?lang=en_us&edition=fundamental","pubTime":"2025-11-01 07:51","pubTimestamp":1761954660,"startTime":"0","endTime":"0","summary":"TORONTO, Oct.  31, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K9A) (“Quantum” or the “Company”), a biopharmaceutical company dedicated to building a portfolio o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/31/3178692/0/en/Quantum-BioPharma-Ltd-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","QNTM","BK4551","BK4007","LCID","BK4596","BK4099"],"gpt_icon":0},{"id":"2577302574","title":"Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication","url":"https://stock-news.laohu8.com/highlight/detail?id=2577302574","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577302574?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:15","pubTimestamp":1761221700,"startTime":"0","endTime":"0","summary":"TORONTO, Oct.  23, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/23/3172010/0/en/Quantum-BioPharma-Licensee-Unbuzzd-Wellness-to-Host-Live-Webinar-for-its-Disruptive-Beverage-Innovation-that-Speeds-Alcohol-Metabolism-Reduces-Symptoms-of-Intoxication.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK4555","BK4181","BK4596","BK4551","HST","BK4099","BK4588","QNTM","BK4007","BK4585","LCID"],"gpt_icon":0},{"id":"2576585129","title":"Press Release: Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2576585129","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576585129?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:30","pubTimestamp":1760963400,"startTime":"0","endTime":"0","summary":"TORONTO, Oct. 20, 2025  -- Quantum BioPharma Ltd.     , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the expiration at 5pm EST of 53,147 warrants . All warrants were issued to hedge funds and investment funds as part of a previous financing completed on October 20, 2020. This represents the very last tranche of warrants issued to hedge funds and investment funds.Quantum BioPharma also re-iterates October 27, 2025 as the record date for the distribution of contingent value rights  to holders of its Class B Subordinate Voting Shares on a one-for-one basis, advancing the Company's previously disclosed plan in the Company's press releases dated June 13, 2025, and October 3, 2025 to deliver a litigation-linked CVR to shareholders of record as of the record d","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4585","BK4588","BK4604","BK4099","LCID","BK4551","QNTM","03160","BK4555","BK4007","BK4596"],"gpt_icon":0},{"id":"2575290228","title":"Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2575290228","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575290228?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:15","pubTimestamp":1760444100,"startTime":"0","endTime":"0","summary":"TORONTO, Oct.  14, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/14/3166171/0/en/Quantum-BioPharma-Ltd-Responds-to-Vague-and-Misleading-Allegations-by-The-Schall-Law-Firm-and-DJS-Law-Group.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LCID","BK4551","BK4099","QNTM","BK4596","BK4555"],"gpt_icon":0},{"id":"2573092821","title":"Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2573092821","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573092821?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:00","pubTimestamp":1759924800,"startTime":"0","endTime":"0","summary":"Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ LawsuitTORONTO, Oct.  08, 2025  (GLOBE NEWSWIRE) -- Quantum Bio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/08/3163260/0/en/Quantum-BioPharma-Announces-Cash-Reward-of-up-to-USD-7Million-for-Proof-of-Market-Manipulation-in-its-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4596","QNTM","LCID","BK4551","USD","PACI.U","BK4007","BK4555"],"gpt_icon":0},{"id":"2572501143","title":"Press Release: Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2572501143","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572501143?lang=en_us&edition=fundamental","pubTime":"2025-10-03 19:00","pubTimestamp":1759489200,"startTime":"0","endTime":"0","summary":"TORONTO, Oct. 03, 2025  -- Quantum BioPharma Ltd.    , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced today that its Board of Directors has established October 27, 2025 as the record date for the distribution of contingent value rights  to holders of its Class B Subordinate Voting Shares on a one-for-one basis, advancing the Company's previously disclosed plan in the Company's press release dated June 13, 2025, to deliver a litigation-linked CVR to shareholders of record as of the record date.-- Will not be listed on any exchange or marketplace;-- Will not carry interest or voting rights;-- Will be redeemable only for cash, and only in the event that the Company. receives net proceeds from the resolution of the Litigation (whether by. \"This record date is a key milestone in aligning potential future recoveries from the Company's Litigation directly with our shareholders through a simple and enforceable right that pays","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4551","BK4596","USD","BK4585","BK4007","BK4588","BK4604","QNTM","03160","TM","BK4099","LCID"],"gpt_icon":0},{"id":"2572514301","title":"Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2572514301","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572514301?lang=en_us&edition=fundamental","pubTime":"2025-10-02 19:57","pubTimestamp":1759406220,"startTime":"0","endTime":"0","summary":"TORONTO, Oct.  02, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/02/3160289/0/en/Quantum-BioPharma-Receives-Final-Reports-for-Two-Key-Studies-of-its-Potential-Breakthrough-Drug-for-Multiple-Sclerosis-Moving-Closer-to-Phase-2-Clinical-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1363072403.SGD","BK4581","LU2089283258.USD","BK4504","LU1668664300.SGD","LU1989772840.SGD","LU0098860793.USD","LU2271345857.HKD","LU1732800096.USD","BK4551","BK4127","IE00BZ1G4Q59.USD","LU1162221912.USD","BK4534","LU0314104364.USD","LU1720051017.SGD","LU1548497426.USD","LU1244550577.SGD","LU0106261372.USD","IE00BKVL7J92.USD","LU2023251221.USD","LU0006306889.USD","LU2347655156.SGD","LU0234570918.USD","LU0158827948.USD","LU2111349929.HKD","BK4596","LU1720051108.HKD","BK4099","LU2357305700.SGD","BK4007","LU0795875086.SGD","QNTM","LU1732799900.SGD","LU1244550494.USD","LU0225283273.USD","LU1074936037.SGD","LU0267386448.USD","LCID","BK4516","LU1244550221.USD","LU0158827781.USD","BK4555","BK4585","LU2089284900.SGD","LU0912757837.SGD","LU0106831901.USD","LU0882574139.USD","LU2133065610.SGD","LU0320765646.SGD"],"gpt_icon":0},{"id":"2572536095","title":"Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2572536095","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572536095?lang=en_us&edition=fundamental","pubTime":"2025-10-01 19:50","pubTimestamp":1759319400,"startTime":"0","endTime":"0","summary":"TORONTO, Oct.  01, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/01/3159409/0/en/Quantum-BioPharma-Welcomes-World-Renowned-Multiple-Sclerosis-Expert-Dr-Jack-Antel-as-Clinical-Development-Advisor-For-Lucid-MS-Trials.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0267386448.USD","LU1363072403.SGD","LU1989772923.USD","LU0795875086.SGD","BK4127","LU0314104364.USD","BK4581","LU0158827948.USD","BK4555","LU1720051108.HKD","BK4596","LU2357305700.SGD","LU1244550494.USD","LU2089284900.SGD","LU1162221912.USD","LU0098860793.USD","QNTM","LU0006306889.USD","LU0106831901.USD","BK4534","LU0106261372.USD","BK4504","LU1720051017.SGD","LU1989772840.SGD","LU2347655156.SGD","LU0234570918.USD","LU1074936037.SGD","LU0882574139.USD","IE00BZ1G4Q59.USD","LU0795875169.SGD","LU1244550577.SGD","LU2111349929.HKD","BK4585","LCID","LU1732800096.USD","LU1244550221.USD","LU1548497426.USD","LU0225283273.USD","BK4516","LU0320765646.SGD","BK4588","LU0912757837.SGD","LU2133065610.SGD","LU2023251221.USD","LU2089283258.USD","LU1668664300.SGD","LU2028103732.USD","BK4551","LU0158827781.USD","LU2271345857.HKD"],"gpt_icon":0},{"id":"2571437380","title":"Press Release: Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2571437380","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571437380?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:40","pubTimestamp":1759146000,"startTime":"0","endTime":"0","summary":"TORONTO, Sept. 29, 2025  -- Quantum BioPharma Ltd.     , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce today the results of its annual general and special meeting of shareholders, held on Friday, September 26, 2025 in person at 801-1 Adelaide Street East, Toronto, ON M5C 2V9 .There were shareholders represented in person or by proxy at the AGSM holding 12 class A multiple voting shares  and 1,769,228 class B subordinate voting shares , representing 100% and 46.352% of the votes attached to the Class A Multiple Voting Shares and Class B Subordinate Voting Shares, respectively, with each Class A Multiple Voting Share entitling the holders thereof to 276,660 votes on all matters.Each nominee listed in the Company's management information circular dat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4596","BK4099","BK4551","LCID","03160","QNTM","TM","BK4604","BK4555","BK4007","BK4588"],"gpt_icon":0},{"id":"2569374701","title":"Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2569374701","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569374701?lang=en_us&edition=fundamental","pubTime":"2025-09-24 20:30","pubTimestamp":1758717000,"startTime":"0","endTime":"0","summary":"TORONTO, Sept.  24, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/24/3155458/0/en/Quantum-BioPharma-Licensee-Unbuzzd-Wellness-to-Host-Live-Webinar-and-Q-A-Session-on-Wednesday-October-1-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4555","BK4585","QNTM","BK4596","BK4099","BK4218","BK4551","LCID","HST","BK4007","BK4588"],"gpt_icon":0},{"id":"2568477975","title":"Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=2568477975","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568477975?lang=en_us&edition=fundamental","pubTime":"2025-09-18 20:10","pubTimestamp":1758197400,"startTime":"0","endTime":"0","summary":"TORONTO, Sept.  18, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/18/3152384/0/en/Health-Canada-Grants-Quantum-BioPharma-a-Product-License-for-Its-Innovative-Product-Qlarity-that-Enhances-Energy-and-Promotes-Metabolism-Mental-Alertness-and-Cognitive-Performance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4007","BK4596","BK4099","QNTM","LCID","BK4551"],"gpt_icon":0},{"id":"2566762429","title":"Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT","url":"https://stock-news.laohu8.com/highlight/detail?id=2566762429","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566762429?lang=en_us&edition=fundamental","pubTime":"2025-09-12 19:50","pubTimestamp":1757677800,"startTime":"0","endTime":"0","summary":"TORONTO, Sept.  12, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/12/3149150/0/en/Quantum-BioPharma-Licensee-Unbuzzd-Wellness-to-Host-Investor-Webinar-on-September-16-2025-at-1-30-PM-PT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4166","BK4555","BK4596","QNTM","PT","BK4181","BK4551","BK4585","BK4007","LCID","BK4099","HST","BK4588","BK4218"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fsdpharma.com","stockEarnings":[{"period":"1week","weight":-0.0842},{"period":"1month","weight":-0.3994},{"period":"3month","weight":-0.5554},{"period":"6month","weight":-0.7447},{"period":"1year","weight":0.7983},{"period":"ytd","weight":-0.1205}],"compareEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0203},{"period":"6month","weight":0.0758},{"period":"1year","weight":0.1366},{"period":"ytd","weight":0.0051}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.023459},{"month":2,"riseRate":0.833333,"avgChangeRate":0.170764},{"month":3,"riseRate":0.166667,"avgChangeRate":0.011191},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.10938},{"month":5,"riseRate":0.166667,"avgChangeRate":0.064462},{"month":6,"riseRate":0.5,"avgChangeRate":0.033021},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.017895},{"month":8,"riseRate":0.5,"avgChangeRate":-0.092936},{"month":9,"riseRate":0,"avgChangeRate":-0.105415},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.136125},{"month":11,"riseRate":0.333333,"avgChangeRate":0.040234},{"month":12,"riseRate":0,"avgChangeRate":-0.179121}],"exchange":"NASDAQ","name":"Quantum Biopharma Ltd.","nameEN":"Quantum Biopharma Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quantum Biopharma Ltd.(QNTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quantum Biopharma Ltd.(QNTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quantum Biopharma Ltd.,QNTM,Quantum Biopharma Ltd.股票,Quantum Biopharma Ltd.股票老虎,Quantum Biopharma Ltd.股票老虎国际,Quantum Biopharma Ltd.行情,Quantum Biopharma Ltd.股票行情,Quantum Biopharma Ltd.股价,Quantum Biopharma Ltd.股市,Quantum Biopharma Ltd.股票价格,Quantum Biopharma Ltd.股票交易,Quantum Biopharma Ltd.股票购买,Quantum Biopharma Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quantum Biopharma Ltd.(QNTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quantum Biopharma Ltd.(QNTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction